Strong Bones, Smart Choices: The Power of Lifting, Medication Awareness, and Pharmacist Partnership

Why Bone Health Is More Important Than Ever

In the U.S., nearly 10 million adults aged 50 and over have osteoporosis, and over 43 million have low bone mass. These silent threats are major drivers of debilitating hip, spine, and wrist fractures, especially among women, who are nearly five times more likely than men to develop osteoporosis at key skeletal sites (Wright et al., 2014; CDC, 2021).

Protecting your bones isn’t just about avoiding injuries, it’s about preserving independence and quality of life as you age.

How Resistance Training Builds Stronger Bones

Bones are far from static. They’re living tissue that adapts to how you use them. Progressive resistance training, such as lifting weights or using resistance bands, stimulates osteoblasts and increases bone mineral density (BMD), most notably at the spine and hips (Kelley et al., 2020).

What the research says:

Resistance training, alone or paired with aerobic activity, leads to significant BMD gains, especially in postmenopausal women (Martyn-St James & Carroll, 2010).
Moderate intensity, multi joint movements performed 2–3 times per week show the best results (Howe et al., 2011).
Adding brisk or uphill walking amplifies benefits (Zhao et al., 2015).
Pairing exercise with adequate protein, calcium, and vitamin D supports optimal bone remodeling (Rizzoli et al., 2014).

Medications That Quietly Undermine Bone Health

Even as you work to build bone, some common medications can chip away at your progress:

Glucocorticoids (e.g., prednisone): Fastest bone loss occurs in the first 3–6 months; risk grows with dose and duration (Buckley et al., 2017).
Aromatase inhibitors: Raise fracture risk compared to tamoxifen (Hadji et al., 2017).
SSRIs: Linked to lower BMD and higher fracture rates in several studies (Wu et al., 2012).
Depot medroxyprogesterone acetate (DMPA): FDA boxed warning for BMD loss with long-term use (FDA, 2010).
Others: Long-term PPIs (Targownik et al., 2010), enzyme-inducing antiepileptics (Pack, 2003), thiazolidinediones (Habib & Lin, 2010), heparin, and GnRH analogs.

Flag these early and review risks, especially if patients are taking multiple long-term medications.

The Pharmacist: Your Bone Health Ally

Pharmacists are uniquely positioned to bridge the gap between movement and medicine.

How pharmacists protect bone health:

Medication Review & Risk Stratification: Identify bone-depleting drugs, recommend alternatives, and add bone protection based on guidelines.
Screening & Monitoring: Prompt DXA scans and FRAX risk assessments.
Exercise-Aware Counseling: Reinforce resistance training, realistic timelines, and dietary strategies.
Care Coordination: Work with prescribers and therapists to manage medication timing and initiate bisphosphonates or denosumab when appropriate.

Pharmacist interventions have been shown to improve osteoporosis management, increase treatment initiation, and enhance patient education (Naunton et al., 2019).

Your Action Plan for Lifelong Bone Health

Lift regularly: 2–3 resistance sessions weekly.
Review your medications with a pharmacist.
Combine movement, nutrition, and screenings.
Team up with your pharmacist for long-term strategy.

Bottom line: Resistance training literally builds bone—but medications can undermine that progress. Pharmacists help patients de-risk, screen, and strengthen their skeletons for the long haul.

References

Buckley, L., Guyatt, G., Fink, H. A., Cannon, M., Grossman, J., Hansen, K. E., … American College of Rheumatology. (2017). 2017 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis & Rheumatology, 69(8), 1521–1537. https://doi.org/10.1002/art.40137

Centers for Disease Control and Prevention (CDC). (2021). Osteoporosis and bone health. https://www.cdc.gov

Food and Drug Administration (FDA). (2010). Depo-Provera (medroxyprogesterone acetate) label. U.S. Food and Drug Administration.

Habib, Z. A., & Lin, J. (2010). Thiazolidinedione use and the risk of fracture. Expert Opinion on Drug Safety, 9(2), 187–214. https://doi.org/10.1517/14740330903496476

Hadji, P., Ziller, V., Kyvernitakis, I., Bauer, M., Haas, G., Schmidt, N., & Diel, I. (2017). Effects of aromatase inhibitors on bone health in breast cancer patients. Journal of Cancer Research and Clinical Oncology, 143(1), 1–12. https://doi.org/10.1007/s00432-016-2262-0

Howe, T. E., Shea, B., Dawson, L. J., Downie, F., Murray, A., Ross, C., … Harbour, R. T. (2011). Exercise for preventing and treating osteoporosis in postmenopausal women. Cochrane Database of Systematic Reviews, 2011(7), CD000333. https://doi.org/10.1002/14651858.CD000333.pub2

Kelley, G. A., Kelley, K. S., & Kohrt, W. M. (2020). Exercise and bone mineral density in men: A meta-analysis. Journal of Bone and Mineral Research, 35(9), 1736–1749. https://doi.org/10.1002/jbmr.4037

Martyn-St James, M., & Carroll, S. (2010). Meta-analysis of resistance training and bone mineral density in postmenopausal women. Journal of Bone and Mineral Research, 25(11), 2276–2290. https://doi.org/10.1002/jbmr.141

Naunton, M., Peterson, G. M., Bleasel, M. D., & Bereznicki, L. R. (2019). Pharmacist-led interventions in osteoporosis management: A systematic review. Osteoporosis International, 30(4), 733–744. https://doi.org/10.1007/s00198-018-4771-6

Pack, A. M. (2003). The association between antiepileptic drugs and bone disease. Epilepsy Currents, 3(3), 91–95. https://doi.org/10.1046/j.1535-7597.2003.03309.x

Rizzoli, R., Boonen, S., Brandi, M. L., Bruyère, O., Cooper, C., Kanis, J. A., … Reginster, J. Y. (2014). Vitamin D supplementation in elderly or postmenopausal women: A 2013 update of the 2008 recommendations. Osteoporosis International, 25(2), 475–494. https://doi.org/10.1007/s00198-013-2416-x

Targownik, L. E., Lix, L. M., Metge, C. J., Prior, H. J., Leung, S., & Leslie, W. D. (2010). Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ, 182(7), 651–657. https://doi.org/10.1503/cmaj.091123

Wright, N. C., Looker, A. C., Saag, K. G., Curtis, J. R., Delzell, E. S., Randall, S., & Dawson-Hughes, B. (2014). The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. Journal of Bone and Mineral Research, 29(11), 2520–2526. https://doi.org/10.1002/jbmr.2269

Wu, Q., Bencaz, A. F., Hentz, J. G., & Crowell, M. D. (2012). Selective serotonin reuptake inhibitor treatment and risk of fractures: A meta-analysis of cohort and case–control studies. Osteoporosis International, 23(1), 365–375. https://doi.org/10.1007/s00198-011-1778-8

Zhao, R., Zhao, M., & Xu, Z. (2015). The effects of different exercises on bone mineral density in postmenopausal women: A meta-analysis. Journal of Sports Medicine and Physical Fitness, 55(12), 1523–1534.